Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · IEX Real-Time Price · USD
1.420
-0.040 (-2.74%)
At close: Feb 26, 2024, 3:58 PM
1.430
+0.010 (0.70%)
After-hours: Feb 26, 2024, 6:40 PM EST
-2.74%
Market Cap 29.53M
Revenue (ttm) n/a
Net Income (ttm) -28.77M
Shares Out 20.22M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,221
Open 1.460
Previous Close 1.460
Day's Range 1.420 - 1.510
52-Week Range 0.760 - 2.140
Beta 1.46
Analysts Strong Buy
Price Target 10.50 (+639.44%)
Earnings Date Mar 21, 2024

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pip... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 4, 2012
Employees 29
Stock Exchange NASDAQ
Ticker Symbol RGLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for RGLS stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 639.44% from the latest price.

Price Target
$10.5
(639.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

7 weeks ago - PRNewsWire

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

3 months ago - PRNewsWire

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease...

3 months ago - PRNewsWire

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

4 months ago - PRNewsWire

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

4 months ago - PRNewsWire

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients ...

5 months ago - PRNewsWire

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , Sept. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

5 months ago - PRNewsWire

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Regulus Therapeutics Inc.

6 months ago - PRNewsWire

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

6 months ago - PRNewsWire

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429  R&D Day to discuss our ADPKD pro...

7 months ago - PRNewsWire

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

7 months ago - PRNewsWire

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

SAN DIEGO , July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

7 months ago - PRNewsWire

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

8 months ago - PRNewsWire

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

SAN DIEGO , June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

8 months ago - PRNewsWire

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Program advances to lead compound evaluation in preclinical in vivo models Preliminary data for in vivo studies are expected in second half of 2023 SAN DIEGO , June 20, 2023 /PRNewswire/ -- Regulus Th...

8 months ago - PRNewsWire

Regulus Therapeutics Strengthens Research & Development Leadership

Appoints Preston S. Klassen, M.D.

9 months ago - PRNewsWire

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Blinded safety data observed so far are encouraging SAN DIEGO , May 16, 2023 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and develop...

10 months ago - PRNewsWire

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 Closed $15.0 million private plac...

10 months ago - PRNewsWire

Regulus Therapeutics Announces $15 Million Private Placement of Equity

SAN DIEGO , April 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

11 months ago - PRNewsWire

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO , April 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t...

11 months ago - PRNewsWire

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Top-line data in the first cohort of RGLS8429-t...

1 year ago - PRNewsWire

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

SAN DIEGO , Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

1 year ago - PRNewsWire

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

1 year ago - PRNewsWire

Regulus Therapeutics Announces Resignation of Board Member

SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (...

1 year ago - PRNewsWire

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations

Additional Preclinical Promotions Round Out Scientific Leadership SAN DIEGO , Nov. 29, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discove...

1 year ago - PRNewsWire